Amphastar Pharmaceuticals (AMPH) Equity Average: 2014-2025
Historic Equity Average for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Sep 2025 value amounting to $767.1 million.
- Amphastar Pharmaceuticals' Equity Average rose 6.47% to $767.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.1 million, marking a year-over-year increase of 6.47%. This contributed to the annual value of $685.9 million for FY2024, which is 17.43% up from last year.
- Per Amphastar Pharmaceuticals' latest filing, its Equity Average stood at $767.1 million for Q3 2025, which was up 1.69% from $754.4 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Equity Average registered a high of $767.1 million during Q3 2025, and its lowest value of $437.8 million during Q4 2021.
- Over the past 3 years, Amphastar Pharmaceuticals' median Equity Average value was $692.9 million (recorded in 2024), while the average stood at $670.9 million.
- In the last 5 years, Amphastar Pharmaceuticals' Equity Average fell by 2.67% in 2021 and then rose by 21.79% in 2024.
- Over the past 5 years, Amphastar Pharmaceuticals' Equity Average (Quarterly) stood at $437.8 million in 2021, then grew by 18.06% to $516.9 million in 2022, then grew by 19.42% to $617.3 million in 2023, then grew by 18.26% to $730.0 million in 2024, then grew by 6.47% to $767.1 million in 2025.
- Its Equity Average stands at $767.1 million for Q3 2025, versus $754.4 million for Q2 2025 and $741.8 million for Q1 2025.